{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:12:16Z","timestamp":1793121136095,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T00:00:00Z","timestamp":1726876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100031531","name":"Travere Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031531","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s41669-024-00527-1","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T20:14:22Z","timestamp":1726949662000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-8479","authenticated-orcid":false,"given":"Zheng-Yi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-7898","authenticated-orcid":false,"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-6525","authenticated-orcid":false,"given":"Nisha C.","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4924-5009","authenticated-orcid":false,"given":"Chunyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7950-7685","authenticated-orcid":false,"given":"Bruce","family":"Hendry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-8492","authenticated-orcid":false,"given":"Claire C.","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-7666","authenticated-orcid":false,"given":"Mo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,21]]},"reference":[{"issue":"2","key":"527_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.36469\/jheor.2021.26129","volume":"8","author":"CS Kwon","year":"2021","unstructured":"Kwon CS, Daniele P, Forsythe A, Ngai C. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. J Health Econ Outcomes Res. 2021;8(2):36\u201345.","journal-title":"J Health Econ Outcomes Res"},{"issue":"2","key":"527_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","volume":"361","author":"A Rajasekaran","year":"2021","unstructured":"Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021;361(2):176\u201394.","journal-title":"Am J Med Sci"},{"issue":"4","key":"527_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"527_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):S1\u2013276.","journal-title":"Kidney Int"},{"issue":"25","key":"527_CR5","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314.","journal-title":"N Engl J Med"},{"issue":"10075","key":"527_CR6","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238\u201352.","journal-title":"Lancet"},{"issue":"3","key":"527_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Inker LA, Floege J, Perkovic V, Boyer-Suavet S, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"527_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037763","volume":"7","author":"AB Lib\u00f3rio","year":"2012","unstructured":"Lib\u00f3rio AB, Santos JPL, Minete NFA, de Alencar DC, Soares AP, Queiroz AL, et al. Proteinuria is associated with quality of life and depression in adults with primary glomerulopathy and preserved renal function. PLoS\u00a0One. 2012;7(5): e37763.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"527_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5114\/aoms.2020.100367","volume":"17","author":"M Mizerska-Wasiak","year":"2021","unstructured":"Mizerska-Wasiak M, Adamczuk D, Cicho\u0144-Kawa K, Miklaszewska M, Szymanik-Grzelak H, Pietrzyk JA, et al. Health-related quality of life in children with immunoglobulin A nephropathy\u2014results of a multicentre national study. Arch Med Sci. 2021;17(1):84\u201391.","journal-title":"Arch Med Sci"},{"key":"527_CR10","unstructured":"Cattran DC, Appel GB, Coppo R, Fervenza FC. IgA nephropathy: treatment and prognosis. 2022. https:\/\/www.uptodate.com\/contents\/iga-nephropathy-treatment-and-prognosis. Accessed 1 Dec 2022."},{"issue":"5","key":"527_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43(5):717\u201328.","journal-title":"Semin Immunopathol"},{"issue":"23","key":"527_CR12","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225\u201336.","journal-title":"N Engl J Med"},{"key":"527_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003965.pub2","author":"M Vecchio","year":"2015","unstructured":"Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2015. https:\/\/doi.org\/10.1002\/14651858.CD003965.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"527_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00007890-200101270-00011","volume":"71","author":"YS Kim","year":"2001","unstructured":"Kim YS, Moon JI, Jeong HJ, Kim MS, Kim SI, Choi KH, et al. Live donor renal allograft in end-stage renal failure patients from immunoglobulin A nephropathy. Transplantation. 2001;71(2):233\u20138.","journal-title":"Transplantation"},{"key":"527_CR15","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3389\/fimmu.2019.01332","volume":"10","author":"G Moroni","year":"2019","unstructured":"Moroni G, Belingheri M, Frontini G, Tamborini F, Messa P. Immunoglobulin A nephropathy. Recurrence after renal transplantation. Front Immunol. 2019;10:1332.","journal-title":"Front Immunol"},{"issue":"5","key":"527_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/ndt\/gfs472","volume":"28","author":"G Moroni","year":"2013","unstructured":"Moroni G, Longhi S, Quaglini S, Gallelli B, Banfi G, Montagnino G, et al. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Nephrol Dial Transplant. 2013;28(5):1305\u201314.","journal-title":"Nephrol Dial Transplant"},{"key":"527_CR17","unstructured":"US Food and Drug Administration. FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. 2021. https:\/\/www.fda.gov\/drugs\/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease. Accessed 1 Dec 2022."},{"key":"527_CR18","unstructured":"Travere Therapeutics. Travere Therapeutics announces positive topline interim results from the ongoing phase 3 PROTECT study of sparsentan in IgA nephropathy. 2021. https:\/\/ir.travere.com\/news-releases\/news-release-details\/travere-therapeutics-announces-positive-topline-interim-results. Accessed 1 Dec 2022."},{"issue":"5","key":"527_CR19","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.kint.2018.12.018","volume":"95","author":"PA Canetta","year":"2019","unstructured":"Canetta PA, Troost JP, Mahoney S, Kogon AJ, Carlozzi N, Bartosh SM, et al. Health-related quality of life in glomerular disease. Kidney Int. 2019;95(5):1209\u201324.","journal-title":"Kidney Int"},{"key":"527_CR20","volume-title":"Measuring and valuing health benefits for economic evaluation","author":"J Brazier","year":"2017","unstructured":"Brazier J, Ratcliffe J, Saloman J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2017."},{"issue":"Suppl 1","key":"527_CR21","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1007\/s10198-013-0508-x","volume":"14","author":"AE Attema","year":"2013","unstructured":"Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA. Time trade-off: one methodology, different methods. Eur J Health Econ. 2013;14(Suppl 1):S53-64.","journal-title":"Eur J Health Econ"},{"issue":"9","key":"527_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/11317060-000000000-00000","volume":"27","author":"DR Wright","year":"2009","unstructured":"Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics. 2009;27(9):713\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"527_CR23","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812\u201321.","journal-title":"Value Health"},{"key":"527_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/PROM.S306228","volume":"12","author":"AB Smith","year":"2021","unstructured":"Smith AB, Hanbury A, Ortiz B, de Zarate I, Hammes F, de Pouvourville G, Buesch K. Eliciting health state utilities for aromatic l-amino acid decarboxylase (AADC) deficiency: a vignette study in France. Patient Relat Outcome Meas. 2021;12:237\u201346.","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"527_CR25","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/ckj\/sfx057","volume":"10","author":"SA Brown","year":"2017","unstructured":"Brown SA, Tyrer FC, Clarke AL, Lloyd-Davies LH, Stein AG, Tarrant C, et al. Symptom burden in patients with chronic kidney disease not requiring renal replacement therapy. Clin Kidney J. 2017;10(6):788\u201396.","journal-title":"Clin Kidney J"},{"issue":"5","key":"527_CR26","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s11136-020-02712-1","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Shaw J, M\u00fchlbacher A, Lee TA, Walton S, Kohlmann T, et al. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off. Qual Life Res. 2021;30(5):1433\u201344.","journal-title":"Qual Life Res"},{"issue":"10","key":"527_CR27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","volume":"34","author":"M Oppe","year":"2016","unstructured":"Oppe M, Rand-Hendriksen K, Shah K, Ramos-Go\u00f1i JM, Luo N. EuroQol protocols for time trade-off valuation of health outcomes. Pharmacoeconomics. 2016;34(10):993\u20131004.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"527_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/0272989X9801800115","volume":"18","author":"LA Lenert","year":"1998","unstructured":"Lenert LA, Cher DJ, Goldstein MK, Bergen MR, Garber A. The effect of search procedures on utility elicitations. Med Decis Mak. 1998;18(1):76\u201383.","journal-title":"Med Decis Mak"},{"issue":"4","key":"527_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","volume":"17","author":"M Oppe","year":"2014","unstructured":"Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17(4):445\u201353.","journal-title":"Value Health"},{"key":"527_CR30","unstructured":"ClinicalTrials.gov. A study of the effect and safety of sparsentan in the treatment of patients with IgA nephropathy (PROTECT). 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03762850. Accessed 1 Dec 2022."},{"issue":"2","key":"527_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391\u2013402.","journal-title":"Kidney Int"},{"issue":"1","key":"527_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","volume":"18","author":"JT Cooper","year":"2020","unstructured":"Cooper JT, Lloyd A, Sanchez JJG, S\u00f6rstadius E, Briggs A, McFarlane P. Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health Qual Life Outcomes. 2020;18(1):310.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"527_CR33","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","volume":"68","author":"I Gorodetskaya","year":"2005","unstructured":"Gorodetskaya I, Zenios S, Mcculloch CE, Bostrom A, Hsu C-Y, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801\u20138.","journal-title":"Kidney Int"},{"issue":"11","key":"527_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165675","volume":"11","author":"MD Jesky","year":"2016","unstructured":"Jesky MD, Dutton M, Dasgupta I, Yadav P, Ng KP, Fenton A, et al. Health-related quality of life impacts mortality but not progression to end-stage renal disease in pre-dialysis chronic kidney disease: a prospective observational study. PLoS\u00a0One. 2016;11(11): e0165675.","journal-title":"PLoS\u00a0One"},{"issue":"11","key":"527_CR35","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1185\/030079905X65277","volume":"21","author":"AJ Lee","year":"2005","unstructured":"Lee AJ, Morgan CL, Conway P, Currie CJ. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin. 2005;21(11):1777\u201383.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"527_CR36","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s11136-012-0207-6","volume":"22","author":"F-J Lin","year":"2013","unstructured":"Lin F-J, Longworth L, Pickard AS. Evaluation of content on EQ-5D as compared to disease-specific utility measures. Qual Life Res. 2013;22(4):853\u201374.","journal-title":"Qual Life Res"},{"issue":"2","key":"527_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1524-4733.2009.00610.x","volume":"13","author":"Y Peeters","year":"2010","unstructured":"Peeters Y, Stiggelbout AM. Health state valuations of patients and the general public analytically compared: a meta-analytical comparison of patient and population health state utilities. Value Health. 2010;13(2):306\u20139.","journal-title":"Value Health"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00527-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00527-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00527-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:03:57Z","timestamp":1736427837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00527-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00527-1","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,21]]},"assertion":[{"value":"28 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study and open access fee were funded by Travere Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mark E. Bensink is an employee of Benofit Consulting, which received consulting fees from Travere Therapeutics, Inc. Bruce Hendry is an employee of Travere Therapeutics, Inc., and holds stock\/options. Zheng-Yi Zhou, Nisha C. Hazra, and Chunyi Xu are employees of Analysis Group, Inc., which has received consulting fees from Travere Therapeutics, Inc. Claire C. Sharpe is an employee of Wilkins & Sharpe, Ltd., which received consulting fees from Travere Therapeutics, Inc. Mo Zhou was an employee of Analysis Group, Inc., at the time of the study, which has received consulting fees from Travere Therapeutics, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study was reviewed and received an exemption determination from ongoing oversight by the Pearl Institutional Review Board according to FDA 21 CFR 56.104 and 45CFR46.104(b)(2): (2) Tests, Surveys, Interviews.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participating individuals.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Research idea and study design: Mark E. Bensink, Mo Zhou, Zheng-Yi Zhou, Nisha C. Hazra, Bruce Hendry, Claire C. Sharpe; data acquisition: Zheng-Yi Zhou,\u00a0Mo Zhou, Nisha C. Hazra; data analysis\/interpretation: Mark E. Bensink, Mo Zhou, Zheng-Yi Zhou, Nisha C. Hazra, Chunyi Xu, Bruce Hendry, Claire C. Sharpe; statistical analysis: Zheng-Yi Zhou, Mo Zhou, Nisha C. Hazra, Chunyi Xu; supervision: Mark E. Bensink, Bruce Hendry, Claire C. Sharpe. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}